Black Hawk Acquisition (BKHA) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Jasper Therapeutics is the larger company by market cap ($9.6 million vs $7.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | JSPR |
|---|---|---|
| Share price | $1.85 | $8.69 |
| Market cap | $7.68M | $9.64M |
| 1-day change | -71.45% | -18.25% |
| YTD return | — | +374.86% |
| 1-year return | — | +411.18% |
| 5-year return | — | -89.44% |
| P/E ratio (TTM) | 5.61 | — |
| EPS (TTM) | $0.33 | $-7.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.33M | $-75.80M |
| 52-week high | $23.00 | $72.60 |
| 52-week low | $1.75 | $8.47 |
| Distance from 52-week high | -91.96% | -88.03% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +130.15% |
| Average volume | 101.40K | 16.89K |
| Shares outstanding | 4.15M | 1.11M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
BKHA vs JSPR FAQ
Which is bigger, Black Hawk Acquisition or Jasper Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $9.64M compared with $7.68M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.